During the recent World Health Assembly, there was a lot of discussion on how to realize tangible progress against non-communicable diseases (NCDs), which today lead to more than 60% of deaths worldwide. WHO Member States nailed down a focused and solid global action plan that should guide them towards the achievement of ambitious targets for...
Read moreIFPMA Statement, EB 133, Item 6.2, Psoriasis Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for the opportunity to provide our perspective on psoriasis. IFPMA represents the global R&D pharmaceutical industry, whose primary contribution to global health...
Read moreWHO Executive Board, 133rd session IFPMA Statement under agenda item 5, “WHO Reform” Delivered by Mario Ottiglio, Director, Public Affairs & Global Health Policy Check against delivery, 30 May 2013 Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry...
Read moreInternational Federation of Pharmaceutical Manufacturers & Associations provided expert commentary on non-communicable diseases, mental and neurological disorders, R&D for diseases of the developing world, counterfeit medicines, vaccines, and neglected tropical diseases Geneva, 28 May 2013, As a nongovernmental organization (NGO) in official relations with the World Health Organization (WHO), the International Federation of Pharmaceutical Manufacturers...
Read moreIFPMA Statement under WHA 66 agenda item 13.2 on Draft action plan for the prevention and control of noncommunicable diseases 2013–2020 Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), for the opportunity to provide our perspective on...
Read moreIFPMA Statement, WHA 66, Item 16.2, Neglected tropical diseases Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world IFPMA highly commends the WHO...
Read moreIFPMA statement under WHA 66 agenda item 16.1 on Global Vaccine Action Plan (GVAP) Delivered by Laetitia Bigger, Senior Manager, Vaccines Policy 25 May 2013 Thank you for the opportunity to contribute to this important discussion. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world. Mr. Chairman,...
Read moreIFPMA Statement, WHA 66, Item 17.2, Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for the opportunity to provide our...
Read moreIFPMA Statement under WHA 66 agenda item 17.1 on Substandard / spurious / falsely-labelled / falsified / counterfeit medical products Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), for the opportunity to provide our perspective on this...
Read moreIFPMA Statement, WHA 66, Item 13.3, Mental Health Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you for the opportunity to contribute to this leading discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations worldwide. IFPMA highly commends the WHO Secretariat for its...
Read more